Ji S, Liu H, Pachella L, Stephenson R, Groisberg R, Weiss S
Front Transplant. 2024; 2:1284740.
PMID: 38993910
PMC: 11235332.
DOI: 10.3389/frtra.2023.1284740.
Rao Ullur A, Cote G, Pelletier K, Kitchlu A
Clin Kidney J. 2023; 16(6):939-951.
PMID: 37261008
PMC: 10229281.
DOI: 10.1093/ckj/sfad014.
Grace de Lima S, Hyrcza M, Monzon J
Case Rep Oncol. 2023; 16(1):137-142.
PMID: 36880029
PMC: 9984937.
DOI: 10.1159/000528414.
Catalano M, Roviello G, Galli I, Santi R, Nesi G
Front Med (Lausanne). 2023; 9:1014257.
PMID: 36606052
PMC: 9807763.
DOI: 10.3389/fmed.2022.1014257.
Joseph A, Lafarge A, Azoulay E, Zafrani L
Cells. 2022; 11(24).
PMID: 36552755
PMC: 9776910.
DOI: 10.3390/cells11243991.
Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.
Kawashima S, Joachim K, Abdelrahim M, Abudayyeh A, Jhaveri K, Murakami N
Korean J Transplant. 2022; 36(2):82-98.
PMID: 35919193
PMC: 9296977.
DOI: 10.4285/kjt.22.0013.
Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020.
Gupta S, Cortazar F, Riella L, Leaf D
Kidney360. 2022; 1(2):130-140.
PMID: 35372904
PMC: 8809100.
DOI: 10.34067/KID.0000852019.
Use of Immune Checkpoint Inhibitors in End Stage Kidney Disease Patients, Single Center Experience and Review of the Literature.
Hirsch J, Wanchoo R, Ng J, Khanin Y, Jhaveri K
Kidney360. 2022; 1(5):399-402.
PMID: 35369378
PMC: 8809292.
DOI: 10.34067/KID.0000422020.
Renal Toxicity.
Abdelrahim M, Abudayyeh A
Adv Exp Med Biol. 2022; 1342:389-397.
PMID: 34972976
DOI: 10.1007/978-3-030-79308-1_16.
Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review.
Kitchlu A, Jhaveri K, Sprangers B, Yanagita M, Wanchoo R
Clin Kidney J. 2021; 14(9):2012-2022.
PMID: 34476087
PMC: 8406068.
DOI: 10.1093/ckj/sfab090.
Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma.
Ishikawa G, Sugiyama T, Ito T, Otsuka A, Miyake H
Int Cancer Conf J. 2021; 10(2):116-118.
PMID: 33786286
PMC: 7947052.
DOI: 10.1007/s13691-020-00458-8.
Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice.
Kuo M, Su P, Huang C, Luo H, Chiu T, Li S
Front Oncol. 2020; 10:584834.
PMID: 33330066
PMC: 7729012.
DOI: 10.3389/fonc.2020.584834.
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?.
Franzin R, Netti G, Spadaccino F, Porta C, Gesualdo L, Stallone G
Front Immunol. 2020; 11:574271.
PMID: 33162990
PMC: 7580288.
DOI: 10.3389/fimmu.2020.574271.
Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period.
Blosser C, Haber G, Engels E
Kidney Int. 2020; 99(6):1430-1438.
PMID: 33159960
PMC: 8096865.
DOI: 10.1016/j.kint.2020.10.018.
Early T cell infiltration is modulated by programed cell death-1 protein and its ligand (PD-1/PD-L1) interactions in murine kidney transplants.
Shim Y, Khedraki R, Dhar J, Fan R, Dvorina N, Valujskikh A
Kidney Int. 2020; 98(4):897-905.
PMID: 32763116
PMC: 7541419.
DOI: 10.1016/j.kint.2020.03.037.
Autophagy-lysosome inhibitor chloroquine prevents CTLA-4 degradation of T cells and attenuates acute rejection in murine skin and heart transplantation.
Cui J, Yu J, Xu H, Zou Y, Zhang H, Chen S
Theranostics. 2020; 10(18):8051-8060.
PMID: 32724457
PMC: 7381746.
DOI: 10.7150/thno.43507.
In Situ Immune Profiling of Heart Transplant Biopsies Improves Diagnostic Accuracy and Rejection Risk Stratification.
Peyster E, Wang C, Ishola F, Remeniuk B, Hoyt C, Feldman M
JACC Basic Transl Sci. 2020; 5(4):328-340.
PMID: 32368693
PMC: 7188920.
DOI: 10.1016/j.jacbts.2020.01.015.
Programmed T cell differentiation: Implications for transplantation.
Crepeau R, Ford M
Cell Immunol. 2020; 351:104099.
PMID: 32247511
PMC: 7198981.
DOI: 10.1016/j.cellimm.2020.104099.
Cutaneous squamous cell carcinoma in the organ transplant recipient.
Bibee K, Swartz A, Sridharan S, Kurten C, Wessel C, Skinner H
Oral Oncol. 2020; 103:104562.
PMID: 32065978
PMC: 7217490.
DOI: 10.1016/j.oraloncology.2019.104562.
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V, Shinagare A, Rennke H, Ghai S, Lorch J, Ott P
Oncologist. 2020; 25(6):505-514.
PMID: 32043699
PMC: 7288631.
DOI: 10.1634/theoncologist.2019-0659.
